Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Assets (2017 - 2025)

Historic Return on Assets for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to 0.47%.

  • Ultragenyx Pharmaceutical's Return on Assets fell 1100.0% to 0.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.47%, marking a year-over-year decrease of 1100.0%. This contributed to the annual value of 0.38% for FY2024, which is 200.0% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Return on Assets is 0.47%, which was down 1100.0% from 0.41% recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Return on Assets ranged from a high of 0.12% in Q1 2021 and a low of 0.54% during Q2 2023
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Return on Assets value was 0.4% (recorded in 2024), while the average stood at 0.39%.
  • In the last 5 years, Ultragenyx Pharmaceutical's Return on Assets surged by 2400bps in 2021 and then plummeted by -2200bps in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Return on Assets (Quarter) stood at 0.3% in 2021, then tumbled by -48bps to 0.45% in 2022, then grew by 1bps to 0.44% in 2023, then grew by 16bps to 0.38% in 2024, then fell by -24bps to 0.47% in 2025.
  • Its Return on Assets stands at 0.47% for Q3 2025, versus 0.41% for Q2 2025 and 0.39% for Q1 2025.